Literature DB >> 20811163

A look at autoimmunity and inflammation in the eye.

Rachel R Caspi1.   

Abstract

Autoimmune and inflammatory uveitis are a group of potentially blinding intraocular inflammatory diseases that arise without a known infectious trigger and are often associated with immunological responses to unique retinal proteins. In the United States, about 10% of the cases of severe visual handicap are attributed to this group of disorders. As I discuss here, experimental models of ocular autoimmunity targeting retinal proteins have brought about a better understanding of the basic immunological mechanisms involved in the pathogenesis of uveitis and are serving as templates for the development of novel therapies.

Entities:  

Mesh:

Year:  2010        PMID: 20811163      PMCID: PMC2929721          DOI: 10.1172/JCI42440

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  117 in total

1.  Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye.

Authors:  P B MEDAWAR
Journal:  Br J Exp Pathol       Date:  1948-02

Review 2.  Aire.

Authors:  Diane Mathis; Christophe Benoist
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

Review 3.  Th1 and Th17 cells: adversaries and collaborators.

Authors:  Jesse M Damsker; Anna M Hansen; Rachel R Caspi
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

4.  Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model. Concomitant regulation by MHC and non-MHC genes.

Authors:  R R Caspi; B G Grubbs; C C Chan; G J Chader; B Wiggert
Journal:  J Immunol       Date:  1992-04-15       Impact factor: 5.422

Review 5.  Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.

Authors:  Srilakshmi M Sharma; Achim R Nestel; Richard W J Lee; Andrew D Dick
Journal:  Ocul Immunol Inflamm       Date:  2009 Nov-Dec       Impact factor: 3.070

6.  Peripheral induction of tolerance by retinal antigen expression.

Authors:  Dale S Gregerson; Neal D Heuss; Ute Lehmann; Scott W McPherson
Journal:  J Immunol       Date:  2009-06-19       Impact factor: 5.422

7.  Major role of gamma delta T cells in the generation of IL-17+ uveitogenic T cells.

Authors:  Yan Cui; Hui Shao; Chen Lan; Hong Nian; Rebecca L O'Brien; Willi K Born; Henry J Kaplan; Deming Sun
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

Review 8.  NOD2-associated diseases: Bridging innate immunity and autoinflammation.

Authors:  Arturo Borzutzky; Ari Fried; Janet Chou; Francisco A Bonilla; Susan Kim; Fatma Dedeoglu
Journal:  Clin Immunol       Date:  2009-05-24       Impact factor: 3.969

Review 9.  Monocyte dependent regulation of autoimmune inflammation.

Authors:  Lindsay B Nicholson; Ben J E Raveney; Markus Munder
Journal:  Curr Mol Med       Date:  2009-02       Impact factor: 2.222

Review 10.  Immunotherapy of autoimmunity and cancer: the penalty for success.

Authors:  Rachel R Caspi
Journal:  Nat Rev Immunol       Date:  2008-12       Impact factor: 53.106

View more
  174 in total

1.  Autoimmunity to neuroretina in the concurrent absence of IFN-γ and IL-17A is mediated by a GM-CSF-driven eosinophilic inflammation.

Authors:  So Jin Bing; Phyllis B Silver; Yingyos Jittayasothorn; Mary J Mattapallil; Chi-Chao Chan; Reiko Horai; Rachel R Caspi
Journal:  J Autoimmun       Date:  2020-06-24       Impact factor: 7.094

Review 2.  Interplay between innate and adaptive immunity in the development of non-infectious uveitis.

Authors:  François Willermain; James T Rosenbaum; Bahram Bodaghi; Holly L Rosenzweig; Sarah Childers; Travis Behrend; Gerhild Wildner; Andrew D Dick
Journal:  Prog Retin Eye Res       Date:  2011-11-22       Impact factor: 21.198

3.  An eye for discovery.

Authors:  Andreas Stahl; Lois E H Smith
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

4.  Inhibition of neovascularization but not fibrosis with the fluocinolone acetonide implant in autosomal dominant neovascular inflammatory vitreoretinopathy.

Authors:  Paul S Tlucek; James C Folk; Jason A Orien; Edwin M Stone; Vinit B Mahajan
Journal:  Arch Ophthalmol       Date:  2012-11

5.  Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one.

Authors:  Marina V Tikhonovich; Aleksei K Erdiakov; Svetlana A Gavrilova
Journal:  Int Ophthalmol       Date:  2017-06-21       Impact factor: 2.031

6.  Caveolin-1 increases proinflammatory chemoattractants and blood-retinal barrier breakdown but decreases leukocyte recruitment in inflammation.

Authors:  Xiaoman Li; Xiaowu Gu; Timothy M Boyce; Min Zheng; Alaina M Reagan; Hui Qi; Nawajes Mandal; Alex W Cohen; Michelle C Callegan; Daniel J J Carr; Michael H Elliott
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-26       Impact factor: 4.799

Review 7.  Vitamin D: Implications for ocular disease and therapeutic potential.

Authors:  Rose Y Reins; Alison M McDermott
Journal:  Exp Eye Res       Date:  2015-02-25       Impact factor: 3.467

8.  IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses.

Authors:  Reiko Horai; Mary J Mattapallil; Wai Po Chong; Phyllis B Silver; Jun Chen; Ru Zhou; Yuri Sergeev; Rafael Villasmil; Chi-Chao Chan; Rachel R Caspi
Journal:  J Autoimmun       Date:  2013-09-07       Impact factor: 7.094

Review 9.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

10.  MHC class II expression and potential antigen-presenting cells in the retina during experimental autoimmune uveitis.

Authors:  Deborah A Lipski; Rémi Dewispelaere; Vincent Foucart; Laure E Caspers; Matthieu Defrance; Catherine Bruyns; François Willermain
Journal:  J Neuroinflammation       Date:  2017-07-18       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.